ABOUT DATAMONITOR HEALTHCARE
- About the CNS pharmaceutical analysis team
EXECUTIVE SUMMARY
- Introduction
- Scope and coverage of the Brief
- Key findings about the topic
- Datamonitor estimates that approximately 67 million insomnia patients will
receive prescribed drug therapy in 2004 across the seven major markets,
although the potential patient population is considerably higher at 238
million across the seven major markets.
- Ambien is currently the market-leading insomnia drug, with a 94% share of
the branded insomnia market. However, the drug will face increasing
competition with the launch of generic zolpidem and numerous novel drugs.
- Sepracor's Estorra and Neurocrine/Pfizer's indiplon are expected to reach
market during 2005, and will drive the growth of the insomnia market, both
reaching blockbuster status within the forecast period.
DIESEASE OVERVIEW
- Disease definition
- Insomnia classification
- Epidemiology
- Prevalence of insomnia
- Gender
- Diagnosis and diagnosis rates
- Treatment
- Economic consequences
- Summary of patient potential
PHARMACOLOGICAL THERAPY
- Benzodiazepines
- Drugs used off-label
- Antihistamines
- Antidepressants
- Unmet needs in insomnia
BRANDED INSOMNIA DRUGS
- Ambien/Stilnox (zolpidem)
- Marketing strategies
- Reformulation
- Demonstrate long-term efficacy and safety of Ambien
- Sanofi-Aventis and insomnia
- Sonata (zaleplon)
- Marketing strategies
- Current market overview
- US market
- Japanese market
- European market
PIPELINE COMPOUNDS
- Indiplon
- Marketing strategies
- Estorra (eszopiclone)
- Marketing strategies
- Estorra versus Indiplon
- TAK-375
- Gaboxadol
FUTURE PERSPECTIVE
- Reformulation strategies
- Sonata
- Ambien CR
- Free drug trials
- Targeting US employers
- Insomnia market forecast
APPENDIX
- Contributing experts
- Bibliography
- Websites
- Research methodology
- Disclaimer
List of Tables
- Table 1: Insomnia patient populations (000s) across the seven major
markets, 2004
- Table 2: Marketed insomnia drugs' revenues in the US, Japan and five major
European markets ($m), 1999-2003
- Table 3: Insomnia R&D pipeline, 2004
- Table 4: Insomnia market forecast, 2003-12 ($m)
List of Figures
- Figure 1: Symptoms of insomnia in the US population
- Figure 2: Characteristics of the ideal hypnotic drug, 2004
- Figure 3: Impact of generic of Zimovane revenues in the five major
European markets
- Figure 4: Revenues of Ambien, Sonata and other marketed insomnia drugs in
the US, Japan and five major European markets ($m), 1999-2003
- Figure 5: Ambien free trial offer
- Figure 6: Insomnia market forecast, 2004-12
|
Related Report
|
View Cart
